Détail de la notice
Titre du Document
Eviprostat®, a drug for benign prostatic hyperplasia, ameliorates the urinary frequency in rats with bladder outlet obstruction
Auteur(s)
SASAKI Yasuo ; TANAKA Mitsushi ; HAMADA Kozo ; ...
Résumé
Eviprostat®, a phytotherapeutic agent, has long been used as a treatment for benign prostatic hyperplasia. The aim of this study was to elucidate the effect of Eviprostat on the urinary frequency in rats with bladder outlet obstruction. Partial urethral obstruction in female rats was made by ligature around the urethra in the presence of an intraluminally placed plastic rod. Several weeks after the urethral obstruction, the rat was placed in a metabolic cage. The number of micturition for 24 hours, voided volume for one episode and total voided volume for 24 hours were analyzed by measuring the expelled urine volume. The number of micturition was significantly increased from 4 to 5 weeks after the urethral obstruction, and the voided volume for one episode was significantly decreased from 4 to 6 weeks after the obstruction, indicating urinary frequency was evident at 4 and 5 weeks after the obstruction. Eviprostat was orally administered at 18mg/kg as ingredient content, twice daily for 9 days to the rats 4 weeks after the obstruction. Eviprostat significantly decreased the number of micturition and tended to increase the voided volume for one episode without influencing the total voided volume. Eviprostat evidently ameliorated urinary frequency caused by urethral obstruction in rats. These results support the efficacy of Eviprostat for the treatment of urinary frequency in the patients with benign prostatic hyperplasia.
Editeur
Life Science
Identifiant
ISSN : 0386-3603 CODEN : YACHDS
Source
Yakuri to chiryo A. 2006, vol. 34, n° 3, pp. 299-304 [6 pages]
Langue
Japonais
Pour les membres de la communauté du CNRS, ce document est autorisé à la reproduction à titre gratuit.
Pour les membres des communautés hors CNRS, la reproduction de ce document à titre onéreux sera fournie sous réserve d’autorisation du Centre Français d’exploitation du droit de Copie.

Pour bénéficier de nos services (strictement destinés aux membres de la communauté CNRS (Centre National de la Recherche Scientifique), de l'ESR français (Enseignement Supérieur et Recherche), et du secteur public français & étranger) :